Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk

FDA's risk evaluation and mitigation strategy for fluoroquinolone antibiotics requires manufacturers to survey patients and prescribers to make sure they understand the risks of tendon injury associated with the products